Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study

Abstract

Background The IMPACT study demonstrated the benefit of interferon beta-1a (IFNβ-1a, Avonex®) two-year change in disability measured by the Multiple Sclerosis Functional Composite (MSFC) in secondary progressive multiple sclerosis (SP-MS) and health-related quality of life (HRQoL) measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI). The IMPACT data permit a detailed assessment of the relation between clinical and self-reported measures.

Methods IMPACT was an international randomized, double-blind, placebo-controlled trial of SP-MS patients. As the MSQLI is only in English, this report includes US and Canadian subjects. Subjects were randomized to weekly intramuscular (im) injections of INb-1a (60 mg) or placebo for 24 months.

Results At baseline and follow-up, MSQLI correlations were generally stronger with the EDSS than with the MSQLI, MSFC but comparable with MSFC components. Combining the two groups, MSQLI changes for those in the best and worst MSFC change quartiles demonstrated a statistical difference for six of the 11 MSQLI scales. Linear regression demonstrated that EDSS change from baseline to month-24 scores was correlated with change in two MSQLI components.

Conclusion These data support the appropriateness of using the MSQLI with individuals who have SP-MS.

Keywords

clinical trials multiple sclerosis Multiple Sclerosis Functional Composite Multiple Sclerosis Quality of Life Inventory quality of life

Get full access to this article

View all access options for this article.

References

Cohen JA , Cutter GR , Fischer JS , Goodman AD , Heidenreich FR , Kooijmans M et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS . Neurology 2002; 59: 679-687 .

European Study Group on Interferon Beta-1b in Secondary Progressive MS. Placebo-controlled multi-center randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis . Lancet 1998; 352: 1491-1497 .

Goodkin DE , the North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial (Abstract) . Neurology 2000; 54: 2352-2352 .

Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPEC-TRIMS) Study Group . Randomized controlled trial of recombinant interferon-beta-1a in secondary progressive MS. Clinical results . Neurology 2001; 56: 1496-1504 .

Freeman JA , Thompson AJ , Fitzpatrick R , Hutchinson M , Miltenburger C , Beckmann K et al. Inter-feron-beta-1b in the treatment of secondary progressive MS: impact on quality of life . Neurology 2001; 57: 1870-1875 .

Damiano AM. Sickness impact profile: user’s manual and interpretation guide. Johns Hopkins University , 1996.

Fischer JS , Rudick RA , Cutter GR , Reingold SC. The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcomes assessment . Mult Scler 1999; 5: 244-250 .

Cutter GR , Baier ML , Rudick RA , Cookfair DL , Fischer JS , Petkau J et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure . Brain 1999; 122: 871-882 .

Rudick RA , Cutter G , Baier M , Fisher E , Weinstock-Guttman B , Mass MK et al. Use of the multiple sclerosis functional composite in predicting disability in relapsing MS . Neurology 2001; 56: 1324-1330 .

10.

Ritvo PG , Fischer JS , Miller DM , Andrews H , Paty D , LaRocca NG. Multiple Sclerosis Quality of Life Inventory: a user’s manual. National Multiple Sclerosis Society , 1997.

11.

Goodkin DE , Hertsgard D , Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests . Arch Phys Med Rehab 1988; 69: 850-854 .

12.

Gronwall DMA. Paced auditory serial-addition task: a measure of recovery from concussion . Percept Motor Skills 1977; 44: 367-373 .

13.

Fischer JS , Jak AJ , Knicker JE , Rudick RA. Administration and scoring manual for the Multiple Sclerosis Functional Composite Measure (MSFC). National Multiple Sclerosis Society , 1999.

14.

Kurtzke J. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 1983; 33: 1444-1452 .

15.

Fischer JS , LaRocca NG , Miller DM , Ritvo PG , Andrews H , Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS) . Mult Scler 1999; 5: 251-259 .

16.

McHorney CA , Ware JEJ , Lu JF , Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups . Med Care 1994; 32: 40-66 .

17.

Schwartz C , Kozora E , Zeng Q. Towards patient collaboration in cognitive assessment: specificity, sensitivity, and incremental validity of self-report . Ann Behav Med 1996; 18: 96-184 .

18.

Beatty W , Monson N. Metamemory in multiple sclerosis . J Clin Exp Neuropsychol 1991; 13: 309-327 .

19.

Taylor R. Relationships between cognitive test performance and everyday cognitive difficulties in multiple sclerosis . Br J Clin Psychol 1990; 29: 251-253 .

20.

Fischer JS. Objective memory testing in multiple sclerosis. In Jensen K , Knudsen L , Stenager EN , Grant I , eds. Mental disorders, cognitive deficits, and their treatment in multiple sclerosis. Liby , 1989: 39-49.